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Introduction
Familial Mediterranean fever (FMF) is an autosomal reces-
sive autoinflammatory disorder due to MEFV mutations
and one of the most frequent Mediterranean genetic
diseases. The observation of many heterozygous patients
in whom a second mutated allele was excluded led to
propose that heterozygosity could be causal; however, this
might often be coincidental due to the very high rate of
mutations in Mediterranean populations.
Objectives
To better delineate the pathogenicity of heterozygosity in
order to help genetic counselling and better manage the
disease.
Methods
Complementary statistical approaches were used: estima-
tion of FMF prevalence at population levels, genotype
comparison in siblings from 63 familial forms, and geno-
type study in 557 patients from four Mediterranean
populations.
Results
At population level, we did not observe any contribution
of heterozygosity to the disease prevalence. In affected sib-
lings of patients carrying two MEFV mutations, 92% carry
two mutated alleles whereas 4% are heterozygous with
typical FMF diagnosis. We also demonstrated statistically
that patients are more prone to be heterozygous than
healthy individuals, as shown by the higher ratio heterozy-
gous carriers/non carriers in patients (p<10-7 - p<0.003).
The risk for heterozygotes to develop FMF was estimated
between 2.1x10-3 and 5.8x10-3 and the relative risk, as
compared to individuals carrying no MEFV mutation,
between 6.3 and 8.1.
Conclusion
This is the first statistical demonstration that heterozygos-
ity is not responsible for classical Mendelian FMF, but
constitutes a susceptibility factor for clinically-similar
complex conditions. We also provide a first estimate of
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